Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Myelodysplastic Syndromes × Actinium × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1

Interventions

venetoclax 2 Specimen Handling 2 vactosertib 1 regorafenib 1 fludarabine phosphate 1 fludarabine 1 ammonium trichloro(dioxoethylene-O,O'-)tellurate 1 aldesleukin 1 X-Rays 1 Photons 1 Melphalan 1 KB004 1 Interleukin-2 1 IL32 protein, human 1 Cyclophosphamide 1 CYC065 1 CA-4948 1 Azacitidine 1 Actinium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06888323 2026-03-18

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon ⚡